Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Labor and delivery units are losing money and struggling to find staff, in rural areas and large cities alike.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

Though some doctors have been trying to classify “obesity” as a “chronic illness,” being fat and being ill aren’t the same ...

Karoline Leavitt, who Donald Trump has chosen as his White House press secretary, once criticized the Capitol insurrection and reposted praise for then–Vice President Mike Pence certifying the 2020 ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Ozempic — or any of the GLP-1 class of diet drugs that includes Wegovy and Mounjaro — hasn’t just changed our nation’s ...

They've been dubbed 'game-changers' in the world of obesity, making the seemingly impossible, possible - significant weight ...

There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...